News Opinion Editor's Corner ACC 2023 What’s Going to Be Hot at ACC/WCC 2023? Shelley Wood February 27, 2023
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 Lancet Commission on CVD in Women Aims to Slash Global Burden Shelley Wood May 17, 2021
News Conference News ACC 2021 Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients Shelley Wood May 16, 2021
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Conference News ACC 2020 More Burnout in Cardiology as COVID-19 Fans the Flames Shelley Wood March 28, 2020
News Conference News ACC 2019 My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay Shelley Wood April 05, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Conference News ACC 2018 My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up Shelley Wood March 27, 2018
News Conference News ACC 2018 Low-Dose, Three-Drug Polypill TRIUMPHs for Blood Pressure Shelley Wood March 12, 2018
News Conference News ACC 2017 My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time Shelley Wood March 23, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017